This study investigated the impact of the COVID-19 pandemic on time to treatment initiation (TTI) for hepatocellular carcinoma (HCC) using the National Cancer Database. While a statistically significant shorter median TTI was observed during the COVID year (2020) compared to pre-COVID years (2017-2019), this difference was not clinically significant. However, the study revealed that vulnerable patient populations (Black race, Hispanic ethnicity, and those with uninsured/Medicaid/Other Government insurance) experienced increased TTI and treatment delays.
Publisher
Ann Surg Oncol
Published On
Apr 26, 2023
Authors
Gordana Rasic MD, Brendin R Beaulieu-Jones MD, MBA, Sophie H Chung MD, Kelsey S Romatoski MD, Kelly Kenzik PhD, Sing Chau Ng MS, Jennifer F Tseng MD, MPH, Teviah E Sachs MD, MPH
Tags
COVID-19
hepatocellular carcinoma
treatment initiation
National Cancer Database
health disparities
vulnerable populations
time to treatment initiation
Related Publications
Explore these studies to deepen your understanding of the subject.